Feature

Rayner Expands US Cataract Platform with Anikavisc Acquisition

Strengthens Rayner’s US cataract portfolio with a fully bundled OVD, IOL and phaco offering

  • March 13, 2026

  • 2 min

Share

Rayner has secured US distribution rights for Anikavisc, an ophthalmic viscosurgical device from Visco Technologies Inc., enhancing its cataract surgery offerings. This acquisition aligns with Rayner's strategy to provide a comprehensive portfolio, including the newly launched FDA-approved Sophi phaco platform and RayOne EMV Toric IOL. The move, welcomed by Vice President Scott Corning, aims to streamline purchasing processes and deliver added value to US customers as Rayner prepares to introduce AI-designed IOL technology by 2026.

Original Source(s)

Rayner Expands US Cataract Platform with Anikavisc Acquisition

  • March 13, 2026

Related Content

Hydrus®: Designed with Purpose

Professor Norbert Pfeiffer explores the features and benefits of the Hydrus® Microstent

  • March 13, 2026

  • 4 min
Lipid-Derived Biomarkers for NAION

TVST study reveals potential new metabolic signal in nonarteritic anterior ischemic optic neuropathy

  • March 13, 2026

  • 4 min
Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.